CJC-1295 Peptide: What Researchers Need to Know in 2026

CJC-1295 peptide is a synthetic growth-hormone-releasing hormone (GHRH) analog that has drawn serious attention from endocrine and metabolic researchers since the mid-2000s. If you're sourcing compounds for controlled laboratory studies, understanding how this peptide behaves at the receptor level, and where the evidence is strong versus still preliminary, matters a great deal. This guide covers the molecular profile, research findings on CJC-1295 peptide benefits, dosage considerations, the DAC variant, and known safety signals, all grounded in peer-reviewed data.

Contents

• What Is CJC-1295 Peptide?
• CJC-1295 vs CJC-1295 with DAC
• Observed Research Benefits
• CJC-1295 Peptide Dosage in Research
• CJC-1295 Side Effects and Safety Signals
• Is CJC-1295 a Steroid?
• Sourcing and Quality Standards
• How to Store and Reconstitute Lyophilized CJC-1295
• Comparison
• Frequently asked questions
• Sources

What Is CJC-1295 Peptide?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) consisting of 29 amino acids, modified at positions 2, 8, 15, and 27 to resist proteolytic degradation. It binds the GHRH receptor on pituitary somatotrophs, triggering pulsatile secretion of endogenous human growth hormone.

CJC-1295 peptide was originally developed by ConjuChem Biotechnologies in the early 2000s as a long-acting GHRH analog for clinical investigation. The parent peptide, GHRH(1-29), is naturally produced in the hypothalamus but degrades rapidly, with a plasma half-life under 7 minutes. CJC-1295 extends that window dramatically through four targeted amino-acid substitutions that block the main enzymatic cleavage sites.

Because it stimulates the pituitary rather than replacing GH directly, CJC-1295 preserves the body's own feedback loops. That mechanistic distinction is one reason endocrine researchers find it a useful tool: you can study GH-axis signalling without flooding the system with exogenous hormone.

The compound is typically supplied as a lyophilized (freeze-dried) white powder, with 5 mg vials being the standard format for laboratory use. Molecular weight is approximately 3,647 Da, and the sequence maps to a modified GHRH(1-29)-NH2 backbone. Purity specifications for research-grade material generally exceed 98% by HPLC analysis.

In controlled in-vitro and animal studies, CJC-1295 has demonstrated reliable GHRH-receptor binding affinity and dose-dependent GH-release responses. These properties have made the CJC-1295 DAC peptide family a recurring subject in peptide-signalling literature, particularly research examining somatotroph physiology and GH secretagogue pharmacokinetics.

CJC-1295 vs CJC-1295 with DAC

CJC-1295 without DAC has a half-life of roughly 30 minutes and produces sharp, short GH pulses. CJC-1295 with DAC (Drug Affinity Complex) covalently binds to albumin, extending the half-life to 6-8 days and producing a sustained GH baseline rather than discrete pulses.

This is one of the most common points of confusion in peptide research, so I want to lay it out clearly. The two compounds share the same core GHRH analog sequence, but the addition of a Drug Affinity Complex (DAC) maleimidoproprionic acid linker to CJC-1295 with DAC allows covalent bonding to circulating albumin in vivo.

Albumin has a half-life of approximately 19 days in humans. By piggybacking onto this carrier protein, the CJC-1295 DAC peptide achieves a terminal half-life of 6 to 8 days, compared to roughly 30 minutes for the non-DAC version. That pharmacokinetic gap has meaningful implications for experimental design.

Researchers studying pulsatile GH release, which mirrors the natural ultradian rhythm seen in healthy young adults, typically prefer the non-DAC compound because it allows timed, controllable GH stimulation. Those studying sustained GH elevation, or modeling conditions where persistent receptor activation matters, may prefer the DAC variant.

From a practical standpoint, CJC-1295 with DAC dosage schedules in published animal studies have ranged from once-weekly subcutaneous administration to bi-weekly protocols, reflecting that longer half-life. The non-DAC version, when used in rodent models, appears in literature at much more frequent intervals, sometimes daily, to maintain consistent receptor stimulation.

Neither variant should be confused with a GH secretagogue receptor (GHSR) agonist like ghrelin or ipamorelin. They act on different receptors (GHRH-R, not GHSR) and produce different downstream profiles. Combining a GHRH analog with a GHSR agonist is a strategy some researchers use to examine synergistic GH-axis effects, and you'll find that combination referenced in the CJC-1295 peptide benefits literature fairly often.

Observed Research Benefits

Peer-reviewed animal and early human studies on CJC-1295 peptide have documented: increased pulsatile GH secretion, elevated IGF-1 levels, improved lean body mass metrics, accelerated lipolysis markers, and enhanced slow-wave sleep architecture in rodent models.

The phrase 'CJC-1295 peptide benefits' appears throughout fitness and biohacking circles, but I'd rather anchor this section in what the controlled research actually shows, because the distinction matters for anyone conducting legitimate laboratory work.

A 2006 phase II clinical trial published in the Journal of Clinical Endocrinology and Metabolism tested single and multiple doses of CJC-1295 in 65 healthy adults. Researchers recorded mean GH concentrations that were 2 to 10 times above baseline, with effects persisting for 6 days or more after a single injection. IGF-1 levels rose 1.5 to 3 times above baseline and remained elevated for 9 to 11 days. Those are significant numbers from a peer-reviewed, placebo-controlled source.

In rodent models, sustained GH elevation driven by GHRH analogs correlates with measurable increases in lean mass, reductions in adipose tissue, and improvements in connective tissue repair markers. While extrapolating animal data to humans carries obvious caveats, these findings have shaped hypotheses that researchers are still testing in 2026.

Slow-wave sleep is another area of active interest. GH secretion is tightly coupled to deep sleep stages, and some rodent studies suggest GHRH analogs may enhance slow-wave sleep duration and quality through central mechanisms, separate from any peripheral GH effect. That neuro-restorative angle has attracted attention from sleep researchers as well as endocrinologists.

It's worth emphasising: all of these CJC-1295 peptide benefits are documented in research contexts. The compound is not approved for human therapeutic use, and PeptideValidation.com supplies it strictly for qualified laboratory research, not clinical or personal use.

CJC-1295 Peptide Dosage in Research

In published human Phase II trials, single CJC-1295 peptide doses ranged from 30 to 60 mcg/kg body weight administered subcutaneously. Rodent studies use weight-scaled doses typically between 10 and 100 mcg/kg, with frequency varying by whether the DAC variant is used.

Dosage is one of the most searched topics around this compound, and honestly, the variability in published protocols can be confusing. Let me break down what the literature actually shows.

The 2006 Teichman et al. trial, which remains the most cited human pharmacokinetic study, used doses of 30, 60, 120, and 250 mcg/kg. The 30 and 60 mcg/kg cohorts showed the most favourable GH-response-to-tolerability profiles. At higher doses, GH elevations were greater but so were the reported adverse events, which I'll cover in the next section.

For the CJC-1295 with DAC dosage used in animal studies, a common protocol involves weekly or bi-weekly subcutaneous administration in the range of 10 to 50 mcg/kg, adjusted for species-specific GH dynamics. Rats, for example, have naturally high baseline GH pulse frequencies compared to humans, so cross-species dose translation is not straightforward.

Non-DAC CJC-1295 peptide dosage in rodent studies tends to be administered daily or every other day, often at 10 to 100 mcg/kg, because the short half-life means receptor stimulation fades quickly. Some researchers combine it with ipamorelin at similar weight-based doses to study synergistic GH secretion.

A critical point for laboratory work: reconstitution accuracy matters as much as the nominal dose. Errors in bacteriostatic water volume, vial handling, or pipetting technique can shift effective concentration significantly, which is one reason working with well-characterised, high-purity lyophilized material from a verifiable supplier is essential. Impure or degraded peptide introduces confounding variables that compromise data integrity.

CJC-1295 Side Effects and Safety Signals

CJC-1295 side effects observed in human Phase II trials include: transient facial flushing, headache, and dizziness (most common at doses above 60 mcg/kg), and mild injection-site discomfort. No serious adverse events or antibody formation against endogenous GHRH were reported in trials lasting up to 28 days.

Any responsible look at CJC-1295 side effects starts with the same 2006 Teichman trial mentioned above, because it's the highest-quality human safety data we have. At doses of 30 to 60 mcg/kg, adverse events were mild and transient. The most common were facial flushing (about 16% of subjects), headache, and brief dizziness, all resolving within hours.

At higher doses (120 to 250 mcg/kg), the incidence of these events rose, which is consistent with what you'd expect from exaggerated GH-axis stimulation. Water retention and transient joint discomfort are side effects associated with elevated GH and IGF-1 generally, and researchers should account for these as potential confounders in studies where body-composition measurements are an endpoint.

One finding that is particularly relevant to long-duration studies: no subjects in the Teichman trial developed antibodies against endogenous GHRH, even with repeated dosing. That's an important safety signal because cross-reactivity with the body's natural hormone could theoretically suppress the GH axis. The data, at least over 28 days, did not support that concern.

Animal studies have not flagged hepatotoxicity or renal toxicity signals at research-relevant doses. However, chronic high-dose rodent studies have noted pituitary hyperplasia, which is a predictable consequence of sustained GHRH-receptor stimulation and a reminder that long-term effects at supra-physiological doses differ from short-term pharmacokinetic studies.

For researchers designing protocols, I've found it useful to build in washout periods and baseline GH/IGF-1 measurements so that any axis suppression or sensitisation becomes detectable as a data point rather than an uncontrolled variable. Since these are research-only compounds, institutional biosafety and ethics review processes should guide study design from the start.

Is CJC-1295 a Steroid?

CJC-1295 is not a steroid. It is a peptide hormone, meaning it is composed of amino acids rather than a cholesterol-derived steroid backbone. It acts on the pituitary gland to stimulate endogenous GH release and does not interact with androgen, estrogen, or glucocorticoid receptors.

This question comes up constantly in search data, and the answer is clean: no, CJC-1295 is not a steroid. Steroids are lipid-based molecules derived from a four-ring cholesterol scaffold. They include sex hormones like testosterone and estradiol, as well as corticosteroids like cortisol. CJC-1295 shares none of that chemistry.

Instead, it belongs to the peptide hormone class, specifically the GHRH analog subfamily. Its 29-amino-acid chain is water-soluble and acts via a G-protein-coupled receptor on the surface of pituitary somatotroph cells, not on intracellular nuclear receptors the way steroid hormones do. The receptor interaction, downstream signalling cascade (cAMP, PKA, CREB), and ultimate effect (GH secretion) are categorically different from steroid pharmacology.

Why does this distinction matter for researchers? Because the regulatory, storage, handling, and safety considerations for peptides differ from those for steroids. Peptides are generally more fragile, requiring cold-chain storage and careful reconstitution. They degrade via proteolysis rather than hepatic metabolism, so the in-vivo clearance pathways are different.

From a research ethics standpoint, peptide hormones and steroid hormones often fall under different institutional review frameworks, and accurate classification is a prerequisite for proper protocol registration. Calling CJC-1295 a steroid in a protocol document would be a factual error that could complicate ethics board approval.

For labs new to peptide signalling research, I'd recommend reviewing the Endocrine Society's classification guidelines on peptide vs. steroid hormones as a foundational reference before designing any CJC-1295-related study.

Sourcing and Quality Standards

Research-grade CJC-1295 peptide should meet at least 98% purity by HPLC, include a certificate of analysis (CoA) from an accredited third-party laboratory, be supplied as lyophilized powder in a sealed vial, and be sourced from a vendor with documented GMP-aligned manufacturing practices.

Quality is not a minor detail in peptide research. It's the foundation that everything else rests on. A compound that is 90% pure might seem close enough, but that remaining 10% of unknown peptide fragments or synthesis byproducts can produce off-target biological effects that invalidate your results.

When evaluating a supplier, the non-negotiables are: an HPLC purity certificate showing 98% or above, mass spectrometry confirmation of correct molecular weight, and a CoA issued by an independent, accredited analytical laboratory. Some suppliers offer only in-house testing, which provides far weaker assurance than third-party verification.

PeptideValidation.com supplies CJC-1295 as a 5 mg lyophilized powder specifically for controlled laboratory studies. The lyophilized format matters because it's the most stable for long-term storage and shipping, it eliminates the stability concerns that come with pre-reconstituted solutions, and it allows researchers to control reconstitution conditions precisely. Lyophilized peptides stored correctly at -20 degrees Celsius can maintain integrity for 24 months or more.

The vendor question also has a regulatory dimension. In most jurisdictions, research peptides sit in a legal grey zone: they're not scheduled substances, but they are also not approved drugs. Purchasing from a supplier that clearly labels products as research use only, maintains batch-level traceability, and does not market to non-researchers is both legally safer and scientifically cleaner.

Price is sometimes used as a quality proxy, but it's an unreliable one. I've seen expensive peptides with poor CoA documentation and reasonably priced vials backed by solid third-party data. The CoA and the analytical method used to generate it are what matter, not the sticker price. If you're evaluating options, ask for the CoA before you order.

How to Store and Reconstitute Lyophilized CJC-1295

Store lyophilized CJC-1295 at -20 degrees Celsius in a sealed vial away from light. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) by injecting solvent slowly down the vial wall, swirling gently (never vortexing). Use reconstituted solution within 30 days when stored at 2-8 degrees Celsius.

Improper handling is one of the most common sources of experimental error in peptide research. Because CJC-1295 is a fragile 29-amino-acid chain, temperature excursions, mechanical agitation, and contamination during reconstitution can all cause aggregation or partial degradation, giving you a compound that no longer matches the one described in your protocol.

Lyophilized vials should stay sealed at -20 degrees Celsius until you're ready to use them. Avoid freeze-thaw cycling on the powder itself, because each cycle can introduce micro-structural damage to the peptide matrix. When you're ready to reconstitute, let the sealed vial equilibrate to room temperature for 5 to 10 minutes before opening, which prevents condensation from entering the vial.

Bacteriostatic water (sterile water with 0.9% benzyl alcohol) is the standard reconstitution medium for CJC-1295 used in in-vivo animal studies because the benzyl alcohol acts as a preservative, extending usable life to approximately 30 days under refrigeration (2 to 8 degrees Celsius). For in-vitro cell culture work, sterile saline or PBS may be preferred to avoid any benzyl alcohol cytotoxicity concerns.

When adding solvent to the vial, inject it slowly along the interior glass wall, letting it run down and hydrate the powder gradually. Do not inject directly onto the lyophilized cake, and do not vortex. Gentle swirling or rolling the vial between your palms is sufficient. A clear, colourless solution indicates successful reconstitution. Any cloudiness or particulate matter suggests degradation or contamination, and the vial should be discarded.

Label every reconstituted vial with the date, concentration, and your initials. Consistent labelling habits protect data integrity and are part of good laboratory practice regardless of the compound being used. After 30 days, discard unused reconstituted solution even if it appears normal, because the peptide bond stability declines measurably past that window.

Comparison

Frequently asked questions

Sources

• Journal of Clinical Endocrinology and Metabolism (Teichman et al., 2006), Cited in the Observed Research Benefits and CJC-1295 Side Effects sections. This Phase II placebo-controlled trial in 65 healthy adults documented GH elevations of 2-10x baseline, IGF-1 rises of 1.5-3x, and mild adverse events (flushing, headache, dizziness) at doses of 30-250 mcg/kg, with no antibody formation against endogenous GHRH.
• Endocrine Society - Classification of Hormones, Cited in the 'Is CJC-1295 a Steroid?' section to support the classification distinction between peptide hormones (amino-acid based, act on membrane receptors) and steroid hormones (cholesterol-derived, act on intracellular nuclear receptors).

Related guides from this series

• Understanding CJC-1295 Peptide: A Researcher's Guide
• CJC-1295 Peptide vs DAC Form: Which to Research
• The Science of CJC-1295 Peptide: What Research Shows
• CJC-1295 Peptide Buyer's Guide: What Researchers Need (2026)